Log In
BCIQ
Print this Print this
 

NEOliquid

  Manage Alerts
Collapse Summary General Information
Company NEO New Oncology AG
DescriptionNon-invasive blood assay that identifies cancer-specific point mutations, insertions, deletions and gene fusions in circulating cell-free DNA (cfDNA)
Molecular Target
Mechanism of Action 
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetect cancer-specific mutations in circulating cell-free DNA (cfDNA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today